Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
Hartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 7, pp. e495-e509
Closed Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Kaifeng Liu, Meijia Li, Yudong Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 43
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
Jad Othman, Nicola Potter, Adam Ivey, et al.
Blood (2024) Vol. 144, Iss. 7, pp. 714-728
Closed Access | Times Cited: 23
Impact of myelodysplasia‐related and additional gene mutations in intensively treated patients with NPM1‐mutated AML
Sibylle Cocciardi, Maral Saadati, Nina Weiß, et al.
HemaSphere (2025) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 1
Targeting the retinoic acid signaling pathway as a modern precision therapy against cancers
Kousalya Lavudi, Shreya Madhav Nuguri, Zianne Olverson, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 37
Advancements and Challenges in the Treatment of AML
Yasmin Abaza, Christine M. McMahon, Jacqueline S. Garcia
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 12
Current status and research directions in acute myeloid leukemia
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia
Cecilia Restelli, Marco Ruella, Luca Paruzzo, et al.
Blood Cancer Discovery (2024) Vol. 5, Iss. 4, pp. 234-248
Closed Access | Times Cited: 9
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Ling Zhou, Yunlong Lu, Wei Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
NPM1‐mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions
Brunangelo Falini
American Journal of Hematology (2023) Vol. 98, Iss. 9, pp. 1452-1464
Open Access | Times Cited: 19
Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia
Alexandra E. Rojek, Benjamin J. McCormick, Joanna Cwykiel, et al.
eJHaem (2024) Vol. 5, Iss. 4, pp. 728-737
Open Access | Times Cited: 5
Antibody drugs targeting SARS-CoV-2: Time for a rethink?
Likeng Liang, Bo Wang, Qing Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116900-116900
Open Access | Times Cited: 4
Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
Uwe Platzbecker, Richard A. Larson, Sandeep Gurbuxani
HemaSphere (2025) Vol. 9, Iss. 2
Open Access
Biology and Management of Acute Myeloid Leukemia With Mutated NPM1
Evan C. Chen, Shai Shimony, Marlise R. Luskin, et al.
American Journal of Hematology (2025)
Closed Access
Frontline Therapy of AML in the Fit and Younger Population—Incorporating Molecularly Targeted Agents
Keith W. Pratz, Harry P. Erba
American Journal of Hematology (2025) Vol. 100, Iss. S2, pp. 16-22
Open Access
Deep learning predicts therapy-relevant genetics in acute myeloid leukemia from Pappenheim-stained bone marrow smears
Jacqueline Kockwelp, Sebastian Thiele, Jannis Bartsch, et al.
Blood Advances (2023) Vol. 8, Iss. 1, pp. 70-79
Open Access | Times Cited: 9
Acute myeloid leukemia management and research in 2025
Hagop M. Kantarjian, Courtney D. DiNardo, Tapan M. Kadia, et al.
CA A Cancer Journal for Clinicians (2024)
Open Access | Times Cited: 3
Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms—A Systematic Review
Aurelia Collados-Ros, Manuel Muro, Isabel Legáz
Biomedicines (2024) Vol. 12, Iss. 1, pp. 208-208
Open Access | Times Cited: 2
Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients
Bianca Serio, Francesco Grimaldi, Lucia Ammirati, et al.
Cancer Reports (2024) Vol. 7, Iss. 4
Open Access | Times Cited: 2
Allogeneic Stem Cell Transplantation in Refractory Acute Myeloid Leukaemia
Roberto Bono, Giuseppe Sapienza, Stefania Tringali, et al.
Cells (2024) Vol. 13, Iss. 9, pp. 755-755
Open Access | Times Cited: 2
Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies
Evan C. Chen, Jacqueline S. Garcia
Acta Haematologica (2023) Vol. 147, Iss. 2, pp. 198-218
Open Access | Times Cited: 6
Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
Hassan Awada, Mina Abdelmalek, Tara Cronin, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Optimal Post-Remission Consolidation Therapy in Patients with AML
Carlos Jiménez Chillón, Richard Dillon, Nigel H. Russell
Acta Haematologica (2023) Vol. 147, Iss. 2, pp. 147-158
Open Access | Times Cited: 5
Improving long-term outcomes with intensive induction chemotherapy for patients with AML
Christoph Röllig
Hematology (2023) Vol. 2023, Iss. 1, pp. 175-185
Closed Access | Times Cited: 5
Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
Ramy Rahmé, Thorsten Braun
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 549-549
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top